The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma

被引:3
作者
Xiang, Xiaoyong [1 ,2 ]
Chen, Peng [1 ,2 ]
Lan, Fengming [1 ,2 ]
Ma, Li [1 ,2 ]
Jin, Jing [1 ,2 ,3 ]
Zhang, Ye [3 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp & Shenzhen Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Shenzhen, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
nasopharyngeal carcinoma; locoregionally advanced; induction chemotherapy; short-term efficacy; PD-1; GROWTH-FACTOR RECEPTOR; CHEMORADIOTHERAPY; MULTICENTER; RADIOTHERAPY; GEMCITABINE; EXPRESSION; PLACEBO; PHASE-3; NPC;
D O I
10.3389/fonc.2023.1110281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThis study aimed to investigate the short-term efficacy and safety of induction chemotherapy (IC) combined with PD-1 inhibitor or anti-EGFR in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Methods and materialsWe retrospectively reviewed the clinical data of 206 patients with LA-NPC, including IC combined with anti-PD-1 (57 patients), IC combined with anti-EGFR (28 patients), and IC alone (121 patients). The short-term efficacy was assessed at the end of IC and one month after overall treatment. According to the RECIST v1.1, the short-term efficacy of cervical lymph nodes and primary nasopharynx foci was divided into complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). The overall response (ORR) was defined as the sum of CR and PR. Acute toxicities were graded according to the CTCAE v5.0. One-way analysis of variance (ANOVA) was used to compare differences in the numerical variables among groups. Fisher Freeman-Halton test or Pearson Chi-square test was used to compare classified variables. ResultsThe ORR rates of primary nasopharynx foci in IC, anti-EGFR, and anti-PD-1 group were 68.60%, 67.9%, and 94.7%, respectively, and the corresponding rates of ORR in cervical lymph nodes were 78.5%, 71.4%, and 93.0%, respectively. There was a statistical difference in the ORR between the three groups. Further analysis showed that after IC or overall treatment, the CR rate of primary nasopharynx foci in the anti-PD-1 group was significantly higher than the other two groups. The most common adverse effects were hematotoxicity, gastrointestinal toxicity, and transaminase elevation. However, there were no statistical differences in the frequency of any common adverse effects between the three groups. ConclusionsThe addition of anti-PD-1 based on IC significantly improved the short-term efficacy of LA-NPC and toxicities were tolerable.
引用
收藏
页数:10
相关论文
共 27 条
  • [1] Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Oropharynx and Nasopharynx
    Badoual, Cecile
    [J]. HEAD & NECK PATHOLOGY, 2022, 16 (01) : 19 - 30
  • [2] Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis
    Blanchard, Pierre
    Lee, Anne
    Marguet, Sophie
    Leclercq, Julie
    Ng, Wai Tong
    Ma, Jun
    Chan, Anthony T. C.
    Huang, Pei-Yu
    Benhamou, Ellen
    Zhu, Guopei
    Chua, Daniel T. T.
    Chen, Yong
    Mai, Hai-Qiang
    Kwong, Dora L. W.
    Cheah, Shie Lee
    Moon, James
    Tung, Yuk
    Chi, Kwan-Hwa
    Fountzilas, George
    Zhang, Li
    Hui, Edwin Pun
    Lu, Tai-Xiang
    Bourhis, Jean
    Pignon, Jean Pierre
    [J]. LANCET ONCOLOGY, 2015, 16 (06) : 645 - 655
  • [3] Cancer incidence and mortality in China, 2007
    Chen, Wan-qing
    Zeng, Hong-mei
    Zheng, Rong-shou
    Zhang, Si-wei
    He, Jie
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (01) : 1 - 8
  • [4] Nasopharyngeal carcinoma
    Chen, Yu-Pei
    Chan, Anthony T. C.
    Quynh-Thu Le
    Blanchard, Pierre
    Sun, Ying
    Ma, Jun
    [J]. LANCET, 2019, 394 (10192) : 64 - 80
  • [5] Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
    Fang, Wenfeng
    Yang, Yunpeng
    Ma, Yuxiang
    Hong, Shaodong
    Lin, Lizhu
    He, Xiaohui
    Xiong, Jianping
    Li, Ping
    Zhao, Hongyun
    Huang, Yan
    Zhang, Yang
    Chen, Likun
    Zhou, Ningning
    Zhao, Yuanyuan
    Hou, Xue
    Yang, Qing
    Zhang, Li
    [J]. LANCET ONCOLOGY, 2018, 19 (10) : 1338 - 1350
  • [6] Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study
    Hong, R. L.
    Hsiao, C. F.
    Ting, L. L.
    Ko, J. Y.
    Wang, C. W.
    Chang, J. T. C.
    Lou, P. J.
    Wang, H. M.
    Tsai, M. H.
    Lai, S. C.
    Liu, T. W.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (09) : 1972 - 1979
  • [7] Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma
    Jin, Shanzhao
    Li, Ruoyan
    Chen, Ming-Yuan
    Yu, Chao
    Tang, Lin-Quan
    Liu, Yan-Min
    Li, Jiang-Ping
    Liu, Yi-Na
    Luo, Yi-Ling
    Zhao, Yifan
    Zhang, Yu
    Xia, Tian-Liang
    Liu, Shang-Xin
    Liu, Qi
    Wang, Guan-Nan
    You, Rui
    Peng, Jing-Yun
    Li, Jiang
    Han, Feng
    Wang, Jianwei
    Chen, Qiu-Yan
    Zhang, Li
    Mai, Hai-Qiang
    Gewurz, Benjamin E.
    Zhao, Bo
    Young, Lawrence S.
    Zhong, Qian
    Bai, Fan
    Zeng, Mu-Sheng
    [J]. CELL RESEARCH, 2020, 30 (11) : 950 - 965
  • [8] Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
    Lee, Anne W. M.
    Ma, Brigette B. Y.
    Ng, Wai Tong
    Chan, Anthony T. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29) : 3356 - +
  • [9] Management of locally recurrent nasopharyngeal carcinoma
    Leea, Anne W. M.
    Ng, Wai Tong
    Chan, Jimmy Y. W.
    Corry, June
    Makitie, Antti
    Mendenhall, William M.
    Rinaldo, Alessandra
    Rodrigo, Juan P.
    Saba, Nabil F.
    Strojan, Primoz
    Suarez, Carlos
    Vermorken, Jan B.
    Yom, Sue S.
    Ferlito, Alfio
    [J]. CANCER TREATMENT REVIEWS, 2019, 79
  • [10] Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma A Multicenter Phase 3 Randomized Clinical Trial
    Li, Wang-Zhong
    Lv, Xing
    Hu, Dan
    Lv, Shu-Hui
    Liu, Guo-Ying
    Liang, Hu
    Ye, Yan-Fang
    Yang, Wen
    Zhang, Han-Xiong
    Yuan, Tai-Ze
    Wang, De-Shen
    Lu, Nian
    Ke, Liang-Ru
    Tang, Wu-Bing
    Tong, Li-Hua
    Chen, Zhi-Jie
    Liu, Ting
    Cao, Ka-Jia
    Mo, Hao-Yuan
    Guo, Ling
    Zhao, Chong
    Chen, Ming-Yuan
    Chen, Qiu-Yan
    Huang, Pei-Yu
    Sun, Rui
    Qiu, Fang
    Luo, Dong-Hua
    Wang, Lin
    Hua, Yi-Jun
    Tang, Lin-Quan
    Qian, Chao-Nan
    Mai, Hai-Qiang
    Guo, Xiang
    Xiang, Yan-Qun
    Xia, Wei-Xiong
    [J]. JAMA ONCOLOGY, 2022, 8 (05) : 706 - 714